-
Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study
Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study Nexviazyme met its primary endpoint, participants alive and free of invasive ventilation, in treatment-naïve infants zero to six months of age in the Baby-COMET phase 3 study Sanofi intends to submit the data to support a regulatory application in the…
-
enParadigm Helps Hospitality Enterprise Save ₹6.5 Crore Through Its AI-Led Hiring Platform
The company’s simulation-led AI evaluation platform assessed 6,000+ candidates, reclaimed 18,000 management hours, cut hiring timelines by 75%, and delivered 87% alignment with expert hiring decisions. MUMBAI, India, June 25, 2026 /PRNewswire/ — enParadigm, an AI-driven talent solutions company, has helped one of India’s leading luxury hospitality enterprises significantly transform its hiring operations by deploying its Interview AI platform. Implemented as part…
-
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants – – Majority of verekitug-treated participants experienced clinically meaningful improvements across key secondary endpoints, including 72% in nasal congestion and 83% in CRSwNP total symptom score – WALTHAM, Mass., June 14, 2026 (GLOBE…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
